Second-generation CAR-T containing CD28 costimulatory molecule can be better activated when exposed to CD80 stimulation on the surface of tumor cells, which makes the second-generation CAR-T cells much stronger than the first-generation CAR-T cells, and also shows better therapeutic effects in clinical treatment. The gene discussed is CD80; the disease is neoplasm.